Wayne Rankin

Wayne Rankin

Auto-generated profile, based on publicly available information

Wayne Rankin

Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia; Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia; SA Pathology, Royal Adelaide Hospital, Adelaide, Australia

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SKSanna-Maria Käkönen
Sanna-Maria Käkönen
KSKatri S. Selander
Katri S. Selander
JCJohn M. Chirgwin
John M. Chirgwin
JYJuan Juan Yin
Juan Juan Yin
SBSuzanne Burns
Suzanne Burns
TGTheresa A. Guise
Theresa A. Guise
Transforming growth factor (TGF)-β promotes breast cancer metastasis to bone. To determine whether the osteolytic factor parathyroid hormone-related protein (PTHrP) is the primary mediator of the tumor response to TGF-β, mice were inoculated with MDA-MB-231 breast cancer cells expressing a constitutively active TGF-β type I receptor. Treatment of the mice with a PTHrP-neutralizing antibody greatly decreased osteolytic bone metastases. There were fewer osteoclasts and significantly decreased tumor area in the antibody-treated mice. TGF-β can signal through both Smad and mitogen-activated protein (MAP) kinase pathways. Stable transfection of wild-type Smad2, Smad3, or Smad4 increased TGF-β-stimulated PTHrP secretion, whereas dominant-negative Smad2, Smad3, or Smad4 only partially reduced TGF-β-stimulated PTHrP secretion. When the cells were treated with a variety of protein kinases inhibitors, only specific inhibitors of the p38 MAP kinase pathway significantly reduced both basal and TGF-β-stimulated PTHrP production. The combination of Smad dominant-negative blockade and p38 MAP kinase inhibition resulted in complete inhibition of TGF-β-stimulated PTHrP production. Furthermore, TGF-β treatment of MDA-MB-231 cells resulted in a rapid phosphorylation of p38 MAP kinase. Thus, the p38 MAP kinase pathway appears to be a major component of Smad-independent signaling by TGF-β and may provide a new molecular target for anti-osteolytic therapy.

1 May 2004 in The Journal of Hand Surgery
Verified
Journal Article
Closed access
NMNicola Massy-Westropp
Nicola Massy-Westropp
WRWayne Rankin
Wayne Rankin
MAMichael Ahern
Michael Ahern
JKJegan Krishnan
Jegan Krishnan
THTrevor C Hearn
Trevor C Hearn

23 May 2016 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
EME. J. Meyer
E. J. Meyer
MNM. A. Nenke
M. A. Nenke
WRW. Rankin
W. Rankin
JLJ. G. Lewis
J. G. Lewis
DTD. J. Torpy
D. J. Torpy
Corticosteroid-binding globulin (CBG, transcortin) is the primary cortisol binding protein. It is a non-inhibitory serine protease inhibitor, capable of conformational change from a high cortisol-binding affinity form to a low affinity form upon cleavage of its reactive centre loop by various proteases, such as neutrophil elastase. The burgeoning inflammatory role of CBG applies to acute, severe inflammation where depletion is associated with mortality, and to chronic inflammation where defects in cortisol delivery may perpetuate inflammation. Naturally occurring human mutations influence a wide range of CBG properties and point toward a role in hitherto unexplained chronic musculoskeletal pain and fatigue disorders as well as potentially affecting fertility outcomes including offspring gender. In vitro and knock-out animal models of CBG propose a role for CBG in cortisol transport to the brain, providing a foundation for understanding the human observations in those with CBG mutations and sex differences in stress-related mood and behaviour. Finally, CBG measurement has a practical role in the estimation of free cortisol, useful in clinical circumstances where CBG levels or cortisol binding affinity is reduced. Taken together, novel data suggest a role for cortisol in targeted cortisol delivery, with implications in acute and chronic inflammation, as well as roles in metabolism and neurocognitive function, implying that CBG is a multifaceted component in the mechanisms of hypothalamic-pituitary-adrenal axis related homeostasis.

1 November 2014 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
LGLucia Gagliardi
Lucia Gagliardi
MNMarni A. Nenke
Marni A. Nenke
TTTilenka R. J. Thynne
Tilenka R. J. Thynne
JBJenny von der Borch
Jenny von der Borch
WRWayne A. Rankin
Wayne A. Rankin
DTDavid J. Torpy
David J. Torpy
Patients with Addison's disease (AD) report impaired subjective health status (SHS). Since cortisol exhibits a robust circadian cycle that entrains other biological clocks, impaired SHS may be due to the noncircadian cortisol profile achieved with conventional glucocorticoid replacement. Continuous subcutaneous hydrocortisone infusion (CSHI) reproduces a circadian cortisol profile, but its effects on SHS have not been objectively evaluated. The aim of this study was to determine the effect of CSHI on SHS in AD. This was a multicentre, double-blind, placebo-controlled trial of CSHI vs oral glucocorticoid therapy. Participants received in random order 4 weeks of: CSHI and oral placebo, and subcutaneous placebo and oral hydrocortisone, separated by a 2-week washout period. SHS was assessed using the Short-Form 36 (SF-36), General Health Questionnaire (GHQ-28), Fatigue Scale (FS), Gastrointestinal Symptom Rating Scale (GSRS); and Addison's Quality of Life Questionnaire (AddiQoL). Participants were asked their (blinded) treatment preference. Twenty-four hour urine free cortisol (UFC) and diurnal salivary cortisol collections compared cortisol exposure during each treatment. Ten participants completed the study. Baseline SHS scores (mean ± SE) were consistent with mild impairment: SF-36 physical component summary 48.4 (± 2.4), mental component summary 53.3 (± 3.0); GHQ-28 18.1 (± 3.3); GSRS 3.7 (± 1.6), and AddiQoL 94.7 (± 3.7). FS was similar to other AD cohorts 13.5 (± 1.0) (P = 0.82). UFC between treatments was not different (P = 0.87). The salivary cortisol at 0800 h was higher during CSHI (P = 0.03), but not at any other time points measured. There was no difference between the treatments in the SHS assessments. Five participants preferred CSHI, four oral hydrocortisone, and one was uncertain. Biochemical measurements indicate similar cortisol exposure during each treatment period, although a more circadian pattern was evident during CSHI. CSHI does not improve SHS in AD with good baseline SHS. This casts some doubt on the potential benefit of circadian cortisol delivery on SHS in AD.

20 November 2014 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
MNM.A. Nenke
M.A. Nenke
WRW. Rankin
W. Rankin
MCM.J. Chapman
M.J. Chapman
NSNatalie Emilia Stevens
Natalie Emilia Stevens
KDKerrilyn R Diener
Kerrilyn R Diener
DTD.J. Torpy
D.J. Torpy

1 February 1998 in European Journal of Cancer
Verified
Journal Article
Closed access
VGV Grill
V Grill
WRW Rankin
W Rankin
TMT.J Martin
T.J Martin